IL17A and melanoma: In addition, treatment of whole blood or isolated mononuclear cells from patients with prostate cancer or melanoma with a PD-1-targeted MAb, followed by activation of T cells, resulted in a pro-inflammatory response characterized by enhanced production of IL-2, IL-6, IL-17, TNF-α, and IFN-γ and reduced production of the Th2 cytokines, IL-5, and IL-13 (90).